Document Classification

Section Type: RESULTS

Text: Fluticasone propionate powder administered by means of Diskus or Diskhaler significantly improved FEV1 (mean increase from baseline of 0. 22 to 0. 24 L ; p < or = 0. 023), clinic morning peak expiratory flow (mean increase from baseline of 48 to 55 L/min ; p < or = 0. 006), patient-measured morning (p < or = 0. 001) and evening (p < or = 0. 003) peak expiratory flow, and asthma symptom scores (in all but the 50 microg Diskus group ; p < or = 0. 036), as well as reduced albuterol use (p < or = 0. 002) and nighttime awakenings (p < or = 0. 019) at endpoint.